Clinical profiles of the enrolled patients
| Clinical profiles | Medical group (n=42) | Endovascular group (n=43) | p Value* |
|---|---|---|---|
| Age | 61.2 (30–76) | 63.8 (39–83) | 0.234 |
| Male:female | 30:12 | 30:13 | 1.000 |
| Initial presentation | 0.649 | ||
| TIA | 13 (31.0%) | 16 (37.2%) | |
| Ischemic stroke | 29 (69.0%) | 27 (62.8%) | |
| Symptomatic qualifying artery | 0.061 | ||
| ICA | 13 (31.0%) | 21 (48.8%) | |
| MCA | 18 (42.9%) | 7 (16.3%) | |
| VA | 5 (11.9%) | 7 (16.3%) | |
| BA | 6 (14.3%) | 8 (18.6%) | |
| Stenosis % of qualifying artery† | 81.5% (70–99) | 83.3% (70–99) | 0.410 |
| Risk factors | |||
| Diabetes mellitus | 22 (52.4%) | 17 (39.5%) | 0.280 |
| Hypertension | 30 (71.4%) | 36 (83.7%) | 0.201 |
| Dyslipidemia | 27 (64.3%) | 29 (67.4%) | 0.821 |
| Smoking | 21 (50.0%) | 23 (53.5%) | 0.829 |
| Antiplatelet medication‡ | 20 (47.6%) | 29 (67.4%) | 0.081 |
| Follow-up duration (months) | 36.0 (1.8–87.4) | 48.2 (1.6–89.0) | 0.024 |
*Independent t test or Fisher exact test.
†Stenosis was measured by the WASID criteria.8
‡Patients who were already prescribed antiplatelet medication before initial presentation.
BA, basilar artery; ICA, internal carotid artery; MCA, middle cerebral artery; TIA, transient ischemic attack; VA, vertebral artery; WASID, Warfarin-Aspirin Symptomatic Intracranial Disease.